Cargando…
Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
BACKGROUND: Currently, there is no consensus on the efficacy and resistance of de novo combination therapy versus monotherapy for treatment naive patients of chronic hepatitis B (CHB). OBJECTIVES: The aim of this study was to evaluate the effectiveness and resistance of de novo combination of lamivu...
Autores principales: | Liu, Fen, Wang, Xiwei, Wei, Fang, Hu, Huaidong, Zhang, Dazhi, Hu, Peng, Ren, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986697/ https://www.ncbi.nlm.nih.gov/pubmed/24673792 http://dx.doi.org/10.1186/1743-422X-11-59 |
Ejemplares similares
-
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016) -
Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
por: Lian, Jiang-Shan, et al.
Publicado: (2019) -
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015) -
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011) -
Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)